GlassScriptPhysician profile
Julia M Johnstone
NPI 1043616808
$2,814.93
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $622 · 2022: $460 · 2023: $1,178 · 2024: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,732.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $487.22 | 2021-2024 | |
| Abbvie INC. | $475.37 | 2021-2024 | |
| Lilly USA, LLC | $381.81 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $231.81 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $216.89 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.27 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Merck Sharp & Dohme LLC | $110.48 | 2021-2024 | Gardasil 9, Gardasil, Capvaxive |
| Biohaven Pharmaceutical Holding Company LTD. | $94.87 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $82.03 | 2021-2024 | Crysvita |
| Amgen INC. | $68.11 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $65.19 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $62.23 | 2021-2024 | Farxiga, Airsupra |
| Biohaven Pharmaceuticals, INC. | $61.02 | 2021 | |
| Abbott Laboratories | $57.62 | 2021-2023 | Freestyle Libre 2 |
| Astellas Pharma US INC | $54.27 | 2021-2024 | Myrbetriq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $48.68 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.83 | 2021 | |
| Axsome Therapeutics, INC. | $27.92 | 2024 | Auvelity |
| Novartis Pharmaceuticals Corporation | $26.02 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $23.62 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.42 | 2024 | |
| Boston Scientific Corporation | $13.94 | 2023 | |
| Idorsia Pharmaceuticals US INC | $13.36 | 2023 | Quviviq |
| Ibsa Pharma INC. | $11.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Johnstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.